Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.
Also called NCT05759078
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT05759078
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT05759078. Randomized; triple masking; primary purpose treatment. Start 2022-09-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
- Acronym
- INFERRCT
- Condition
- Myocardial Infarction, Acute
- Intervention (Drug)
- Ferinject
- Intervention (Drug)
- Sodium Chloride 0.9% Inj
- Lead sponsor
- Wroclaw Medical University
Record details
- Record id
cardio:ct-nct05759078- Content hash
7b947dc8ffb28e4ad8b2fe0d0de6f97e17eec9fd83c8f8ef7f969d1836dfd199